文献速递心脑血管急症消化、代谢与肾脏急症

移动健康技术支持路径对多病共存房颤患者房颤相关不良事件的影响:mAFA-II随机临床试验

The Effects of Implementing a Mobile Health-Technology Supported Pathway on Atrial Fibrillation-Related Adverse Events Among Patients With Multimorbidity: The mAFA-II Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2021-12-01
一句话结论在40个中心的多病共存房颤患者中,mHealth技术支持的ABC路径整合管理较常规护理显著降低卒中或血栓栓塞、全因死亡和再住院复合终点(HR 0.37)。

该研究为mAFA-II前瞻性整群随机试验的预设辅助分析,纳入中国40个中心1890例至少合并2种慢性病的房颤患者。干预组接受mHealth技术支持的ABC路径(A抗凝/防卒中、B更好症状控制、C心血管疾病及合并症管理)整合管理,对照组接受常规护理。中位随访约419-457天,干预组复合终点(卒中或血栓栓塞、全因死亡、再住院)显著降低(HR 0.37;95%CI 0.26-0.53;P<.001),再住院单独亦显著降低(HR 0.42;95%CI 0.27-0.64;P<.001)。C标准相关急性冠脉综合征、心衰和未控制血压发生率干预组低于对照组(27例[3.2%] vs 145例[13.7%];HR 0.29;95%CI 0.19-0.45;P<.001)。

要点

  • 多病共存(≥2种慢性病)房颤患者接受mHealth支持的ABC路径管理,复合终点(卒中或血栓栓塞、全因死亡、再住院)较常规护理显著降低(HR 0.37;95%CI 0.26-0.53;P<.001)。
  • 再住院单独分析亦显著降低(HR 0.42;95%CI 0.27-0.64;P<.001)。
  • ABC路径C标准相关事件(急性冠脉综合征、心衰、未控制血压)干预组3.2%(27例) vs 常规护理组13.7%(145例),HR 0.29;95%CI 0.19-0.45;P<.001。
  • 按年龄、既往卒中、性别亚组分析,干预组主要复合终点和再住院的HR一致低于常规护理组。

适用人群与场景

  • 纳入标准:成年房颤患者,至少合并2种慢性长期疾病(多病共存定义:≥2种慢性长期疾病)。
  • 研究场景:中国40个中心,mAFA-II试验延长随访期间(2018年6月至2021年4月)的预设辅助分析。

处置流程与药物剂量

  • 干预措施:mHealth技术支持的整合管理(mAFA干预),实施ABC路径:A抗凝/避免卒中;B更好症状控制;C心血管疾病及合并症管理。
  • 对照措施:常规护理。

研究设计与关键结果

  • 研究设计:mAFA-II前瞻性整群随机试验的预设辅助分析,纳入1890例多病共存房颤患者,来自中国40个中心。
  • 干预组833例(平均[SD]年龄72.0[12.0]岁;女性278例[33.4%]),平均随访419[257]天;常规护理组1057例(平均[SD]年龄72.8[13.0]岁;女性443例[41.9%]),平均随访457[154]天。
  • 主要复合终点(卒中或血栓栓塞、全因死亡、再住院):干预组较常规护理组显著降低(HR 0.37;95%CI 0.26-0.53;P<.001)。
  • 再住院单独分析:干预组较常规护理组显著降低(HR 0.42;95%CI 0.27-0.64;P<.001)。
  • ABC路径C标准相关事件(急性冠脉综合征、心衰、未控制血压):干预组27例(3.2%) vs 常规护理组145例(13.7%),HR 0.29;95%CI 0.19-0.45;P<.001。
  • 亚组分析(年龄、既往卒中、性别):干预组主要复合终点和再住院的HR一致低于常规护理组。

证据类型、等级与局限

  • 证据类型:前瞻性整群随机试验(mAFA-II)的预设辅助分析。
  • 试验注册:WHO国际临床试验注册平台(ICTRP)注册号ChiCTR-OOC-17014138。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,基于mHealth技术的整合管理促进ABC路径实施,可减少老年多病共存房颤患者有意义的临床不良事件(较常规护理)。
  • 适用人群:成年房颤且至少合并2种慢性长期疾病的多病共存患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The Mobile Health Technology for Improved Screening and Optimized Integrated Care in Atrial Fibrillation (mAFA-II) trial is a prospective cluster randomized trial that found a significant reduction in the composite clinical outcome of stroke or thromboembolism, all-cause death, and rehospitalization among patients with atrial fibrillation (AF) who used a mobile health (mHealth) technology that implemented the Atrial Fibrillation Better Care (ABC) pathway (ie, A, anticoagulation/avoid stroke; B, better symptom control; and C, cardiovascular disease and comorbidity management) compared with those receiving usual care. Multimorbidity (defined as ≥2 chronic long-term conditions) is common in older patients with AF, but the impact of integrated or holistic care (based on the ABC pathway) on clinical outcomes in this population is uncertain.

OBJECTIVE: To evaluate whether implementation of the integrated ABC pathway, supported by mHealth technology, would reduce AF-related adverse events in patients with multimorbidity.

DESIGN, SETTING, AND PARTICIPANTS: This prespecified ancillary analysis of data from the extended follow-up of the mAFA II trial was conducted between June 2018 and April 2021. Adult patients with AF were included in the analysis if they had at least 2 comorbidities. Participants were enrolled across 40 centers in China.

INTERVENTION: Integrated care supported by mHealth technology (mAFA intervention) vs usual care.

MAIN OUTCOMES AND MEASURES: The main outcome was the composite outcome of stroke or thromboembolism, all-cause death, and rehospitalization. Cox proportional hazard modeling was performed for adverse outcomes after adjusting for cluster effect and baseline risk factors.

RESULTS: Of 1890 patients, 833 (mean [SD] age, 72.0 [12.0] years; 278 [33.4%] women) with multimorbidity were allocated to the intervention group (ABC pathway), with a mean (SD) follow-up of 419 (257) days, and 1057 patients (mean [SD] age, 72.8 [13.0] years; 443 [41.9%] women) with multimorbidity were allocated to usual care, with a mean (SD) follow-up of 457 (154) days. Compared with usual care, the composite outcome of stroke or thromboembolism, all-cause death, and rehospitalization was significantly reduced in the intervention group (hazard ratio [HR], 0.37; 95% CI, 0.26-0.53; P < .001), as were rehospitalizations alone (HR, 0.42; 95% CI, 0.27-0.64; P < .001). For the C criterion of the ABC pathway, rates of acute coronary syndrome, heart failure, and uncontrolled blood pressure during follow-up were lower in the intervention group than the usual care group (27 patients [3.2%] vs 145 patients [13.7%]; HR, 0.29; 95% CI, 0.19-0.45; P < .001). Subgroup analyses by age, prior stroke, and sex demonstrated consistently lower HRs for the primary composite outcome and rehospitalization for patients with AF allocated to the intervention group compared with patients receiving usual care.

CONCLUSIONS AND RELEVANCE: In this study, mHealth technology-based integrated care that facilitated the implementation of the ABC pathway reduced meaningful clinical adverse events in older patients with AF and multimorbidity vs usual care.

TRIAL REGISTRATION: WHO International Clinical Trials Registry Platform (ICTRP) Registration number: ChiCTR-OOC-17014138.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Yao Y, Guo Y, Lip GYH, et al. The Effects of Implementing a Mobile Health-Technology Supported Pathway on Atrial Fibrillation-Related Adverse Events Among Patients With Multimorbidity: The mAFA-II Randomized Clinical Trial. JAMA Netw Open. 2021. PMID: 34932104. doi:10.1001/jamanetworkopen.2021.40071

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。